Cue Biopharma, Inc. (CUE) Stock Forecast
CUE analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 3 analysts
- Price target
- $88.00 average of analyst targets
- Upside to target
- +426.6% from the latest close
- Next earnings
- November 11, 2026 EPS estimate $-4.04
- 52-week range
- $5.31 – $37.84
CUE analyst ratings
3 analystsNumber of analysts at each rating.
CUE price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
CUE earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$2.24 | −$4.04 | −$1.27 | −$2.10 | −6.8% | 3 |
| Current fiscal year (2026) | −$25.01 | −$32.12 | −$18.63 | −$8.40 | −197.7% | 3 |
| Next fiscal year (2027) | −$7.44 | −$8.67 | −$5.17 | −$25.01 | +70.2% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
CUE revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $1.0M | $0 | $2.1M | −51.9% | 3 |
| Current fiscal year (2026) | $15.6M | $13.6M | $17.7M | −43.1% | 3 |
| Next fiscal year (2027) | $8.7M | $5.0M | $15.6M | −44.6% | 3 |
CUE EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
CUE revenue: reported and forecast
CUE EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.91 | −$1.91 | −$1.42 | −$1.34 | −$2.24 | +17.5% | 1 up · 0 down |
| Current fiscal year (2026) | −$6.64 | −$6.64 | −$21.45 | −$25.01 | −$25.01 | +276.7% | 0 up · 1 down |
| Next fiscal year (2027) | −$9.45 | −$9.45 | −$6.83 | −$7.44 | −$7.44 | −21.2% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
CUE earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; CUE beat in 9 of 12.
What analysts expect from CUE
3 analysts cover Cue Biopharma; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $88.00, 426.6% above the latest close of $16.71. Analysts expect earnings of −$25.01 per share for 2026, −197.7% from a year earlier. For 2027 the average estimate is −$7.44 per share on revenue of $8.7 million. Cue Biopharma beat the EPS estimate in 9 of the last 12 quarters.
Related: CUE income statement, CUE key metrics, CUE chart. See the CUE stock overview for the latest quote and news.
CUE forecast FAQ
What is Cue Biopharma's price target?
The average analyst price target for Cue Biopharma is $88.00, 426.6% above the latest close of $16.71.
Is Cue Biopharma a buy, hold or sell?
Of 3 analysts covering Cue Biopharma, 3 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Cue Biopharma's EPS forecast?
Analysts forecast −$25.01 per share for 2026 (range −$32.12 to −$18.63); for 2027 the estimate is −$7.44.
What is Cue Biopharma's revenue forecast?
The average revenue estimate for 2026 is $15.6 million, growth of −43.1%; for 2027 it is $8.7 million.
When does Cue Biopharma report earnings?
Cue Biopharma is expected to report results for the quarter ending September 30, 2026 on November 11, 2026; the EPS estimate is $-4.04.
Does Cue Biopharma usually beat earnings estimates?
Cue Biopharma reported EPS at or above the analyst estimate in 9 of the last 12 quarters.